WHWK
Whitehawk Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.20
+2.94%Sep 14, 2026, 01:30 UTC
Whitehawk Therapeutics presented two real-world analyses at WCLC 2026 in Seoul supporting PTK7 as a durable ADC target in pretreated EGFR wild-type NSCLC, reinforcing the rationale for its next-generation PTK7-directed ADC HWK-007 in Phase 1 development.
Source:Sep 10, 2026, 21:07 UTC
Whitehawk Therapeutics appointed Vijay Iyengar as a Class III director effective September 9, 2026, with an initial stock option award for 76,080 shares.
Aug 6, 2026, 12:00 UTC
Whitehawk Therapeutics reported its financial results for the quarter ended June 30, 2026, and provided corporate highlights.
Source:Jul 21, 2026, 11:05 UTC
Akari Therapeutics entered a strategic research collaboration with Whitehawk Therapeutics.
Source: